355 Results
Sort By:
Published on July 27, 2016
Results from a recent clinical analysis by investigators at the Medical University of South Carolina (MUSC) and the Ralph H. Johnson VA Medical Center (VAMC) have revealed disparities in circulating levels of vitamin D and expression of pro-inflammatory genes, at the transcriptome-level, between African-American (AA) patients with prostate cancer compared…
Published on July 7, 2016
A team of researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, along with colleagues at seven other world-leading cancer centers in the US, utilized a simple saliva test to analyze DNA of patients with advanced prostate cancer. The new study, “Inherited DNA-Repair Gene…
Published on June 29, 2016
A team of investigators led by researchers at the University of Toronto has identified a set of prostate cancer biomarkers for use with non-invasive liquid biopsies for the identification of aggressive tumors before surgery. This new study—“Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer”—published recently in Nature Communications advances…
Published on January 4, 2016
Prostate cancer is a relatively common disease with high morbidity and mortality; it is expected to kill more than 27,000 men this year in the U.S. alone. Screening strategies for prostate cancer have recently changed. The PSA (prostate specific antigen) test, introduced in the 1980s, was performed routinely for years.…
Published on November 10, 2015
Arguably, there are few things men look less forward to than the thought of prostate examination. The reasons for their trepidation range from the comical to somber reality of facing the second most common form of cancer among men worldwide—prostate cancer—with over 1.2 million cases diagnosed in 2012 alone. The…
Published on September 1, 2015
GenomeDx Biosciences reported that its commercially available Decipher® testing platform identified, with statistical significance, a set of prostate cancer biomarkers predictive of aggressive disease in African American men after radical prostate surgery. This represents the first and only study describing a set of genomic markers that have the ability to…
Published on May 21, 2015
Based on the most current data, approximately 14% of men will be diagnosed with prostate cancer at some point during their lifetime. If detected early, long term clinical prognosis is very good, however in many cases, prostate cancer can become metastatic and drug resistant tumor rates are on the rise. …
Published on January 27, 2022
The strongest evidence to date has been provided that links BRCA mutations to prostate and pancreatic cancer risk. The study was published this week in the Journal of Clinical Oncology. This team analyzed data from almost 3,200 families with one or more members with the BRCA1 mutation and almost 2,200 families…
Published on September 22, 2021
The US FDA has granted Paige Prostate de novo marketing authorization, making it the first artificial intelligence (AI)-based pathology product to be approved. Paige Prostate is used with the company’s FullFocus digital pathology viewer, approved earlier, to detect prostate cancer. “The approval is a landmark achievement in the field of…
Published on May 10, 2018
Sponsor: Qiagen Qiagen has launched two novel liquid biopsy panels to evaluate circulating tumor cells (CTCs) in the growing field of research into molecular mechanisms in prostate and lung cancers. The AdnaTest ProstateCancerPanel AR-V7 Kit provides insights into tumor biology by detecting the androgen receptor splice variant 7 in CTCs…
Published on March 26, 2024
A single mutation in MUTYH, a gene known to cause colorectal cancer, may cause other solid tumors, according to a study of over 350,000 patient biopsy samples conducted by researchers at the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins Bloomberg School of Public Health, and Foundation Medicine. Their findings…
Published on March 19, 2024
AstraZeneca is acquiring Fusion Pharmaceuticals for $2B. Fusion is a developer of next-generation radioconjugates (RCs) for precision medicine. Fusion’s lead program is alpha-emitting radiopharmaceutical FPI-2265, a small molecule targeting prostate cancers expressing PSMA (Prostate-specific membrane antigen), which is in Phase II for patients with metastatic castration resistant prostate cancer with…
Published on February 26, 2024
A new process tested at University of Kentucky (UK) expands access to germline genetic testing for cancer patients by reporting research-grade germline sequencing to the clinical oncology team. Over a third of pathogenic/likely pathogenic germline variants (PGVs) identified using a universal testing strategy would have been missed by a guideline-based…
Published on February 7, 2024
A large Swedish study has shown that people undergoing surgery for cancer have an increased risk for venous thromboembolism (VTE) that persists for about two to four months postoperatively but varies by cancer type. “The results highlight the need for individualized venous thromboembolism risk evaluation and prophylaxis regimens for patients…
Published on January 31, 2024
European cancer mortality predictions for 2024 highlight a concerning increase in colorectal cancer deaths among people aged 29–45 years that the researchers suggest is linked to increasing rates of overweight and obesity. For the 14th consecutive year, Carlo La Vecchia, professor of Medical Statistics and Epidemiology at the University of Milan…